

Date:									
Patient I.D.:			_						
Country / Province:			_						
Report Type: \square Initia	ıl 🗆 F	Follow u	ıp						
Exposure during pregna	ancy:	\square M	Iaternal	Paternal					
Paternal Information									
Date of birth		Age	Heigh	t	Weight		Rhesus Fac	ctor	
(DD-MMM-YY	YYY)								
			Years	□ cm □in		\square Kgs \square lbs			
Ethnicity: Asian	Black	☐ Cau	ıcasian 🗆 Hispaı	nic 🗆 Other,	specify:				
Medical History									
Risk Factor	Yes No Risk Factor Frequency								
				Never	Occas	sionally	Often	Previously	
								/Quit	
Hepatitis			Substance						
			Abuse						
Hypertension			Alcohol						
Psychiatric Illness			Smoking						
Epilepsy									-
Diabetes									1
HIV									-
Other Notable									1
Health Disorders									
/Conditions: Please									
describe									
	1				1		1	l .	_



Maternal Information															
Date of birth (DD-MMM-YYYY)		Age	Height		Weight		Rhesus Factor								
		Years	□ cm □ir	□ cm □in		□ lbs									
Ethnicity: ☐ Asian ☐ Black ☐ Caucasian ☐ Hispanic ☐ Other, specify:															
MEDICAL HISTORY															
Risk Factor	Yes	No	Risk Factor		Frequency										
				Never	Occ	casionally	Often	Previously /Quit							
Hepatitis			Substance Abuse												
Hypertension			Alcohol												
Psychiatric Illness			Smoking												
Epilepsy															
Diabetes															
HIV															
Other Notable Health Disorders /Conditions: Please describe															
Immunizations:															
Immunization			Yes, Date (DD-MMM-YYY	YY):		No								
Rubella				`											
Toxoplasmosis															
CMV															
Was a contraception method used? ☐ Yes ☐ No ☐ Unknown If yes, please check type of contraception:															
☐ Oral contraception (ty	pe not l	known)		☐ Oral contrace	ption (Progesterone	e)								
☐ Contraceptive Implant ☐ Intra-uterine device															
☐ Oral contraception (C	estroge:	n + Prog	gesterone)												
☐ Transdermal contraception ☐ Contraceptive injection															
□ Condom															
History of □ normal or □ abnormal menstrual cycles															
mistory of intertility \Box	i es	\sqcup \square	U				History of infertility ☐ Yes ☐ No								



First Day of Last Menstrual Period (LMP) (DD-MMM-YYYY):
Estimated Delivery Date (DD-MMM-YYYY): Specify method of calculation:
☐ LMP ☐ Ultrasound Date (DD-MMM-YYYY):
☐ Other, please specify:
Did you become pregnant while on teriflunomide? Yes No If you got pregnant while on teriflunomide, was accelerated elimination used? Yes No
Teriflunomide Dosage at conception:
Gestational Age at Last Dose:
Duration of Treatment with Product while Pregnant:
Did you become pregnant after teriflunomide discontinuation? ☐ Yes ☐ No
If yes, was accelerated elimination used? Yes No No Yes, was accelerated elimination used? Yes, was accelerated elimination used. Yes, was accelerated elimination used. Yes, was accelerated elimination used. Yes, was accelerated eliminat
If yes, did you become pregnant within 11 days of teriflunomide discontinuation? ☐ Yes ☐ No If accelerated elimination was not used, did you become pregnant within 2 years of teriflunomide discontinuation? ☐ Yes ☐ No
If accelerated elimination was not used, did you become pregnant within 2 years of teriflunomide discontinuation? ☐ Yes ☐ No
PATIENT'S MEDICAL HISTORY (include information on familial disorders, known risk factors or conditions that may affect the outcome of the pregnancy e.g. alcohol, smoking, other substance consumption, hypertension, eclampsia, diabetes including gestational, infections during pregnancy, environmental or occupational exposure that may pose a risk factor):
PREVIOUS OBSTETRIC HISTORY - provide details on all previous pregnancies below, including abortion or stillbirth:
Gestation Weeks at Delivery:
Outcome of the pregnancy including any previous maternal complications and previous fetal / neonatal abnormalities and type:
Family History:
Is there any history of congenital abnormalities, children dying young, chromosomal abnormalities, developmental delays or hereditary diseases in paternal or maternal family? Yes No Unknown
If yes, please specify:



Blood relationship between parents? ☐ Yes ☐ No ☐ Unknown (If yes, specify degree)									
DRUG INFORMATION - please list all medications, including OTC medications, and dietary supplements taken prior to or during pregnancy									
			Treatme	ent Dates		Week of p	regnancy		
Drug Name	Daily Dose	Route	Start (DD-MMM- YYYY):	Stop (DD-MMM- YYYY):	Indication	Start	Stop		
Were administere If yes, which drug									
Have any specific	PRENATAL TESTING Have any specific tests, e.g. amniocentesis, ultrasound, maternal serum AFP, chorionic villi sampling, fetal stress test, genetic screening or other been performed during the pregnancy so far?								
□ Yes □ No □	Unknown								
If yes, please speci	ify test date and	results:							
Test	Date: Results (DD-MMM-YYYY)								
PREGNANCY OUTCOME									
Pregnancy Ongoing: Yes No If yes, Gestational age: (weeks) Number of embryos / foetus(es):									
Last ultrasound sca ☐ Normal ☐ Abn	an date (DD-MM normal, please sp	IM-YYYY) ecify:	:						
Delivery Date: (Dl	D-MMM-YYYY):							



	os/veniouse \square Cac	sarean section					
Status of amniotic fluid: □ Clear □ Not clear							
Placenta: Normal Abnormal							
Medications provided during delivery: □ yes, please specify □ No							
Delivery duration:							
Maternal complications	s or problems relate	d to birth:					
Abortion Date:							
☐ Therapeutic ☐ Ele Please, specify reason a ☐ Unspecified:	and any abnormaliti	es (if known):					
At week Complication:							
☐ Mother died☐ Neonate died☐	d (DD-MMM-YYY ed (DD-MMM-YYY	Y): /Y):	_				
MATERNAL PREG	NANCY ASSOCIA	ATED EVENTS					
as requested to th	ne Sponsor and	reaction during pregnancy	nce Program (http	ata collection form and submit s://www.canada.ca/en/health-			
as requested to th	ne Sponsor and	reaction during pregnancy to the Canada Vigilar	nce Program (http	s://www.canada.ca/en/health-			
as requested to th canada/services/drugs-	ne Sponsor and health-products/me	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	nce Program (http action-reporting.html	s://www.canada.ca/en/health-) Form Tracking			
as requested to th canada/services/drugs-	ne Sponsor and health-products/me	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	nce Program (http action-reporting.html	s://www.canada.ca/en/health-) Form Tracking			
as requested to th canada/services/drugs-	ne Sponsor and health-products/me	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	nce Program (http action-reporting.html	s://www.canada.ca/en/health-) Form Tracking			
as requested to the canada/services/drugs- Date	ne Sponsor and -health-products/me Drug	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	Outcome	s://www.canada.ca/en/health-) Form Tracking			
as requested to the canada/services/drugs- Date	ne Sponsor and -health-products/me Drug	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	Outcome	s://www.canada.ca/en/health-) Form Tracking			
as requested to the canada/services/drugs- Date First trimester Follow-	ne Sponsor and -health-products/me Drug -up (please provide o	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea	Outcome Pelopment):	s://www.canada.ca/en/health-) Form Tracking			
as requested to the canada/services/drugs- Date First trimester Follow-	ne Sponsor and -health-products/me Drug -up (please provide o	reaction during pregnancy to the Canada Vigilar deffect-canada/adverse-rea Adverse Event details of embryo/fetal dev	Outcome Pelopment):	s://www.canada.ca/en/health-) Form Tracking			



CHILD INFORMATION Neonate						
	C. d					
☐ Live [Normal] ☐ Live with congenital abnormality ☐ Stillbirth at week						
Please specify any abnormalities:						
☐ Full term ☐ Premature Number of weeks ☐ Post-matu	ure Number of weeks					
Sex: □ Male □ Female						
Height: cms Weight:	kgs					
Apgar Scores:1 min5 mins	10 mins					
Head circumference: cms						
☐ Breast Fed ☐ Bottle Fed						
Neonatal Illness, developmental delay or immaturity? Yes, Pl	lease specify	□ No				
Corrective treatment Required? Yes, Please specify	□ No					
Transfer to ICU or paediatric department? □ Yes, please provide details of location and contact information □ No						
For additional information, (please provide copies of relevant documentation)						
ASSESSMENT OF PREGNANCY OUTCOME						
SERIOUSNESS CRITERIA						
☐ Non-serious ☐ Congenital anomaly/birth defect ☐ Death of mother or neonate						
☐ Involved or prolonged inpatient hospitalization ☐ Life-threatening (immediate risk of death)						
☐ Other significant medical events (may jeopardise the patient or require intervention to prevent one of other criteria)						
☐ Resulted in persistent or significant disability/incapacity						
Reporter Information						
Name:	Title:					
Contact address:	Institution:					
	Department:					
	Phone:					
E-mail:	Fax:					



Healthcare professional: \square Yes \square No)	If yes, please specify occupation:		
Did patient give consent to follow up with	their Healthcare	Patient Name:		
Practitioner for pregnancy outcome and at	intervals of 1 week,			
6, 12 and 24 months post-delivery?				
Healthcare Practitioner:				
Name:		Telephone:		
Address:		Email:		
Completed By				
Name:	Signature:		Date (DD/MMM/YYYY):	